<?xml version="1.0" encoding="UTF-8" standalone="no"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:admin="http://webns.net/mvcb/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/">

<channel rdf:about="http://www.bmj.com">
<title>Latest headlines from BMJ</title>
<link>http://www.bmj.com</link>
<description></description>
<prism:eIssn>1756-1833</prism:eIssn>
<prism:publicationName>BMJ</prism:publicationName>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-101107.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-101112.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-101110.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-101104.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-101099.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/395/bmj-2026-100989.short?rss=1"/>
 </rdf:Seq>
</items>
<image rdf:resource="http://www.bmj.com/icons/site/logo.bmj.gif"/>
<xhtml:meta content="noindex" name="robots" xmlns:xhtml="http://www.w3.org/1999/xhtml"/></channel>
<image rdf:about="http://www.bmj.com/icons/site/logo.bmj.gif">
<title>BMJ</title>
<url>http://www.bmj.com/icons/site/logo.bmj.gif</url>
<link>http://www.bmj.com</link>
</image>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-101107.short?rss=1">
<title><![CDATA[The plan to allow physician assistants to see undifferentiated patients is irresponsible and poorly evidenced]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-101107.short?rss=1</link>
<description><![CDATA[The Leng Review became a deep disappointment after it was first published in summer 2025.1 Instead of being the moment when physician and anaesthesia assistant roles were reined in and refocused on supporting members of healthcare teams, it simply became another example of delaying tough decisions.As the BMA said at the time, it was an inadequate response to a patient safety scandal, particularly in its lack of support for a national scope of practice for physician assistants (PAs), and its failure to clearly reject PAs seeing undifferentiated patients.It was the latter that was most ominous—we have seen far too many examples of patient harm resulting from PAs being put in the position of being the only staff member that saw gravely ill patients when it could make a difference. The case of Emily Chesterton was only the most prominent of these.2Although the prescription fell well short, Leng’s diagnosis was accurate....]]></description>
<dc:creator><![CDATA[Tom Dolphin]]></dc:creator>
<dc:date>2026-10-09T08:11:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-101107</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-101107</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[The plan to allow physician assistants to see undifferentiated patients is irresponsible and poorly evidenced]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>Opinion</prism:section>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_10</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-101112.short?rss=1">
<title><![CDATA[Flu, covid, and winter pressure: &#x201C;Ominous&#x201D; signs of pressure build in hospitals, officials warn]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-101112.short?rss=1</link>
<description><![CDATA[Health officials are warning of “ominous” signs of winter pressure already building in hospitals in England, as new data show flu levels soaring for this time of year.The UK Health Security Agency (UKHSA) said that flu levels were currently higher than the previous four years at the start of the agency’s winter reporting season.The UKHSA’s first weekly winter respiratory virus surveillance report1 shows that, while still at very low levels, flu has been rising since August, suggesting a potential early influenza season.The weekly reports are based on a range of indicators provided by GPs, hospitals, laboratories, and the wider community. This first report recorded that flu positivity—based on a percentage of people who test positive for the virus in hospital—was 6.5% in the week ending 4 October, up from 5% the week prior. In comparison, the previous four years have seen figures of about 1-3% at this time of year.Overall,...]]></description>
<dc:creator><![CDATA[Rosa Furneaux]]></dc:creator>
<dc:date>2026-10-09T08:11:00-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-101112</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-101112</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Flu, covid, and winter pressure: &#x201C;Ominous&#x201D; signs of pressure build in hospitals, officials warn]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_9</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-101110.short?rss=1">
<title><![CDATA[Is the flu season starting early&#x2014;and when should I get vaccinated?]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-101110.short?rss=1</link>
<description><![CDATA[Has the flu season started early?For the second year in a row, it looks like the influenza season has started early in England.“It is very early in the season, but the number of hospital admissions for flu are the highest that I can remember seeing at this time of year,” says Frankie Swords, national medical director at NHS England, speaking at a briefing on winter viruses on 8 October.The latest surveillance report from the UK Health Security Agency (UKHSA)—covering 28 September to 4 October 2026—shows that influenza activity is increasing, with a flu test positivity rate of 6.5%, up from 5% the previous week.1Meanwhile, hospital admissions for flu are at 1.97 per 100 000. As this is the first week of reporting on this figure, there is no comparison.The agency says that, although levels are still low, “flu trends have been rising since August, and there are possible signs that...]]></description>
<dc:creator><![CDATA[Elisabeth Mahase]]></dc:creator>
<dc:date>2026-10-09T07:51:12-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-101110</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-101110</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Is the flu season starting early&#x2014;and when should I get vaccinated?]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>Feature</prism:section>
<prism:subsection1>Features</prism:subsection1>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_8</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-101104.short?rss=1">
<title><![CDATA[ADHD and autism review: NHS must move away from diagnosis linked support system, report says]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-101104.short?rss=1</link>
<description><![CDATA[ADHD and autism diagnosis in England needs a “fundamental shift,” say the authors of a major government backed review.The Fonagy review1 was tasked with investigating rising demand for mental health, attention deficit/hyperactivity disorder (ADHD), and autism services in England and the factors driving this.Chaired by the clinical psychologist Peter Fonagy, the review was commissioned by then health and social care secretary Wes Streeting, against a backdrop of surging demand for NHS services in these areas. It found that more than 254 000 people were on the autism assessment waiting list in December 2025, while 560 000 were waiting for an assessment for ADHD.The report adds that estimates using NHS data suggest that autism has increased among 6-11 year olds more than 20-fold and among 12-17 year olds more than 40-fold.Published today, the almost 600 page report warns that “continuing as we are is not sustainable.” It advises, “The current system...]]></description>
<dc:creator><![CDATA[Rosa Furneaux]]></dc:creator>
<dc:date>2026-10-09T06:36:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-101104</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-101104</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[ADHD and autism review: NHS must move away from diagnosis linked support system, report says]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_7</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-101099.short?rss=1">
<title><![CDATA[GLP-1s: Novo Nordisk and Eli Lilly face lawsuits over vision loss and eye damage]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-101099.short?rss=1</link>
<description><![CDATA[Dozens of people claiming to have sustained eye damage from using GLP-1 medications are suing Eli Lilly and Novo Nordisk, the makers of the blockbuster drugs.1Semaglutide and tirzepatide are now among the most widely used drugs to treat type 2 diabetes and promote weight loss.Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist marketed by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus. Tirzepatide, which acts on GLP-1 and glucose dependent insulinotropic polypeptide (GIP) receptors, is produced by Eli Lilly and available under the brand names Mounjaro and Zepbound.The condition at the centre of the lawsuits is non-arteritic anterior ischaemic optic neuropathy (NAION). It is sometimes described as a “stroke” of the optic nerve and is the most common acute optic neuropathy in people over 50.2Kevin Gendreau, an obesity medicine physician at the Weight & Wellness Center at Signature Healthcare in Brockton, Massachusetts, said of NAION: “Blood flow to...]]></description>
<dc:creator><![CDATA[Alessio Cozzolino]]></dc:creator>
<dc:date>2026-10-09T04:06:13-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-101099</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-101099</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Diabetes]]></dc:subject>
<dc:title><![CDATA[GLP-1s: Novo Nordisk and Eli Lilly face lawsuits over vision loss and eye damage]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_6</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/395/bmj-2026-100989.short?rss=1">
<title><![CDATA[Supporting equity, diversity, and inclusion in research]]></title>
<link>http://www.bmj.com/content/395/bmj-2026-100989.short?rss=1</link>
<description><![CDATA[A lack of equity, diversity, inclusion, and accessibility (EDIA) considerations is a well described challenge that threatens the scientific and ethical integrity of healthcare research.1 Underrepresentation is costly, unjust, and harms patients.1 Unintentional exclusion of patients who may most benefit from trial evidence is a central focus of many efforts to improve EDIA considerations in research, with the exclusion of black participants from cancer trials being an important example.1 Intentional exclusion of pregnant23 or cognitively impaired45 participants from trials that may most benefit these populations is an emerging area of concern. Further, a lack of understanding of structural discrimination relevant to the trial discipline can lead to erroneous conclusions. An important example is attributing findings from observational studies showing worse outcomes from covid-19 infection in black populations6 to biological mechanisms7 without considering how systemic overestimation of blood oxygen by pulse oximetry used on skin of colour8 influences access to treatments...]]></description>
<dc:creator><![CDATA[Gold C Adiele, Shannon M Ruzycki]]></dc:creator>
<dc:date>2026-10-09T03:46:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-100989</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-100989</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Supporting equity, diversity, and inclusion in research]]></dc:title>
<prism:publicationDate>2026-10-09</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:subsection1>Editorial</prism:subsection1>
<prism:volume>395</prism:volume>
<prism:issueIdentifier>oct09_5</prism:issueIdentifier>
</item>
</rdf:RDF>